C
Carlo M. Croce
Researcher at Ohio State University
Publications - 1156
Citations - 199822
Carlo M. Croce is an academic researcher from Ohio State University. The author has contributed to research in topics: microRNA & Cancer. The author has an hindex of 198, co-authored 1135 publications receiving 189007 citations. Previous affiliations of Carlo M. Croce include University of Nebraska Medical Center & University of California, Los Angeles.
Papers
More filters
Journal ArticleDOI
Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.
Lucia Casadei,Lucia Casadei,Federica Calore,Chad J. Creighton,Michele Guescini,Kara Batte,Kara Batte,O. Hans Iwenofu,Abeba Zewdu,Abeba Zewdu,Danielle Braggio,Danielle Braggio,Kate Lynn J. Bill,Kate Lynn J. Bill,Paolo Fadda,Francesca Lovat,Gonzalo Lopez,Gonzalo Lopez,Pierluigi Gasparini,James L. Chen,James L. Chen,Raleigh D. Kladney,Raleigh D. Kladney,Gustavo Leone,Gustavo Leone,Dina Lev,Carlo M. Croce,Raphael E. Pollock,Raphael E. Pollock +28 more
TL;DR: The possibility that the pattern of circulating miRNAs may identify recurrence prior to radiological detectability is established, establishing the possibility that insight into disease outcome and as a possible approach to monitor treatment efficacy is provided.
Patent
Microrna-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Lung Cancer
TL;DR: In this article, the authors proposed methods of diagnosing whether a subject has, or is at risk for developing, lung cancer, comprising measuring the level of at least one miR gene product in a test sample from said subject.
Journal ArticleDOI
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers
Pierluigi Gasparini,Luciano Cascione,Matteo Fassan,Francesca Lovat,Gulnur Guler,Serdar Balci,Cigdem Irkkan,Carl Morrison,Carlo M. Croce,Charles L. Shapiro,Kay Huebner +10 more
TL;DR: Treatment choice and new drug development should consider this new subtyping and miRNA expression signature in planning low toxicity, maximum efficacy therapies.
Journal ArticleDOI
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme
Sung Suk Suh,Ji Young Yoo,Gerard J. Nuovo,Young-Jun Jeon,Seokho Kim,Tae Jin Lee,Taewan Kim,Arianna Bakac̀s,Hansjuerg Alder,Balveen Kaur,Rami I. Aqeilan,Rami I. Aqeilan,Flavia Pichiorri,Carlo M. Croce +13 more
TL;DR: There is a recurrent autoregulatory circuit involving expression of p53, E2F1, and MYC to regulate the expression of miR-25 and -32, which are miRNAs that, in turn, control p53 accumulation.
Journal ArticleDOI
MicroRNA 29 Targets Nuclear Factor-κB–Repressing Factor and Claudin 1 to Increase Intestinal Permeability
QiQi Zhou,QiQi Zhou,Stefan Costinean,Carlo M. Croce,Alan R. Brasier,Shehzad Merwat,Scott A. Larson,Sarpreet Basra,G. Nicholas Verne +8 more
TL;DR: Intestinal tissues from patients with IBS-D had increased levels of MIR29A and B, but reduced levels of Claudin-1 (CLDN1) and nuclear factor-κB-repressing factor (NKRF), which reduces expression of CLDN1 and NKRF to increase intestinal permeability.